Egalet's OXAYDO Receives Pharmaceutical Composition Patent Protection Until 2024

Pharmaceutical Investing

Egalet which develops specialty pharmaceuticals for pain management and other conditions, today announces a new patent has been issued for OXAYDO.

Egalet (NASDAQ:EGLT), which develops specialty pharmaceuticals for pain management and other conditions, today announces a new patent has been issued for OXAYDO. This product was originally licensed from Acura Pharmacueticals.
According to the press release:

The United States Patent and Trademark Office (USPTO) issued patent 9,492,443 broadly covering immediate-release pharmaceutical compositions comprising an opioid formulated with Acura Pharmaceutical’s proprietary Aversion^® Technology intended to discourage common routes of abuse, including snorting. The patent offers protection through 2024.

Egalet’s CEO, Bob Rade, said the following:

“Issuance of this patent further highlights the uniqueness of the OXAYDO formulation, the only approved immediate-release oxycodone designed to discourage abuse via one of the most common routes of oxycodone abuse—snorting.”

Read the full press release here.

egalet oxaydo pain patent patent protection united states Company News